the mean age of participants was 36 years, 65% (n = 36) had leukemia diagnosis and 71% (n = 39) had undergone allogenic transplantation. In the Quality of Life Questionnarie -Core30 instrument, the pain symptom was significant between the first and second stages, and loss of appetite between the third and fourth stages, both in the allogenic group. In the Functional Assessment Cancer Therapy -Bone Marrow Transplantation, the functional well-being domain was significant between the third and fourth stages, also in the allogenic group. Conclusions: although the aggressiveness of treatment affects quality of life, patients consider it satisfactory after the first year. There are few significant differences between autologous and allogenic patients, and both groups have recovered in the course of the process.
During the therapeutic process, the patient undergoes some critical stages in which complications, besides putting their life at risk, can negatively affect their QoL, as symptoms that have a disabling potential may appear (16, 18) . In addition to the physical complications, the patient may suffer with emotional and social changes during treatment. They may feel fear and anguish, and miss the family and friends, since social isolation is necessary in the early stages of treatment.
The QoL of patients worsens as the severity of the symptoms increases (19) . Knowing the specific changes in the QoL of the patient at each stage of the treatment enables the professionals involved in this context, especially the nurse, to establish an individualized and effective care plan, assisting the patient in facing their clinical condition, as well as aiming at a better survival.
In this sense, it is relevant to carry out studies focused on this theme.
Thus, the objective of the present study was to evaluate the QoL of adult patients with hematological cancer submitted to HSCT in the different stages of treatment during the first year and to compare the autologous and allogenic transplantation modalities. into functional and symptom scales and its results are calculated according to the EORTC Scoring Manual (20) .
The FACT-BMT is divided into domains and its results are calculated as described in the FACIT Scoring Manual (21) . 
Results
The sociodemographic characterization of the sample showed that the mean age was 36 years, 53%
(n = 29) were male, 55% (n = 30) were married or declared stable union. Regarding education, 44% (n = 24) declared having completed high school and 64% (n = 35) declared themselves to be economically active.
Regarding the clinical characterization, 65% (n = 36) presented some type of leukemia and 71% (n = 39) had undergone allogenic HSCT.
The results expressed in Table 1 scale, the means demonstrate increased fatigue in the autologous group after 360 days in relation to the pre-HSCT stage; in this scale, the higher the mean, the more intense the symptomatology. Marques ACB, Szczepanik AP, Machado CAM, Santos PND, Guimarães PRB, Kalinke LP. 
Discussion
HSCT is a complex and aggressive treatment, with a large number of variables that must be controlled so that patients' lives are not jeopardized or their QoL is compromised. During the study, 20 patients (36.36% of the sample) died. The mortality rate associated with treatment is expressed in national and international literature. In Brazil, a study conducted in Campinas-SP, Brazil, with 62 patients submitted to HSCT, showed a death rate of 21% in the period before one year after transplantation (22) . In Iran, a longitudinal study of 587 patients submitted to HSCT revealed that the mean survival time of patients was 517 days (23) .
Despite the significant mortality rate, a significant proportion of patients survives after HSCT and demands
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support, as well as care at different stages of treatment.
In this context, health professionals must know the profile of these patients and the changes they suffer in their QoL during the course of the therapeutic process.
With regard to sociodemographic analysis, the mean age of the study was 36 years, with extremes between 18 and 69 years. This finding coincides with those found in a study conducted in São Paulo, Brazil, with 71 adult patients submitted to HSCT, whose mean age was 37 years, ranging from 18 to 65 years (24) .
It is important to emphasize that the mean age of the present study belongs to the age group that would normally be at the peak of one's productive life, In addition, the survey revealed that 55% (n = 30) are married or declared to be in a stable union, data confirmed by similar studies conducted in Brazil and abroad (8, (25) (26) (27) . The presence of a spouse or partner can serve as an emotional support to the patient who undergoes transplantation from the time of diagnosis and at different stages of treatment, especially during hospitalization, when social isolation is relatively long.
Regarding the type of transplantation, the results of the present study differ from results found in studies conducted in Spain and India, in which 59%
and 70% of HSCTs, respectively, were autologous (28) (29) .
Importantly, the place where the research was carried out is considered a world reference transplantation center also due to the amount of allogenic HSCTs that it performs annually.
The domains of QoL measured by the QLQ-C30
and FACT-BMT instruments made it possible to identify the changes that occur during the first year after the .
A study carried out in Spain evaluated the QoL of patients submitted to autologous and allogenic HSCT and revealed that the overall QoL is worse at two months compared to baseline; however, it improves at nine months after HSCT, confirming a positive evolution throughout the therapeutic process. This leads to conclude that the type of HSCT did not influence the QoL in the evaluated period. Nevertheless, a significant difference between the groups was observed in the physical scale (28) .
The physical function, personal performance and It is noteworthy that in the first months the patient suffers from the residual effects of drugs received, since the conditioning phase and many of these have side effects or adverse effects with potential to increase the symptoms, thus impacting the QoL.
As for the loss of appetite symptom, it was more intense in the autologous group only in the pre-HSCT stage; in all other stages, the means of the allogenic group were higher, with a significant difference between the groups after100 days (p = 0.031). National and international studies highlight the loss of appetite as one of the most present symptoms during HSCT; it has a substantial increase during hospitalization and remains a problem for up to six months after HSCT (4, 8, 19, 30) . This A study conducted in Turkey with 82 adult patients submitted to HSCT showed that fatigue, pain and loss of appetite become exacerbated after transplantation and emphasized that patients should be evaluated individually in all domains of QoL, as the results of this evaluation will serve as a basis for nursing to put in place effective interventions that will assist patients in coping with these symptoms (19) .
The 
Conclusion
The diagnosis of hematologic cancer alone is already a stressful factor for the patient and his/her
family. Besides this, the treatment to which they will be submitted has numerous risks, including death. The 
